Insmed is a more stable company today than ever. No other product in its history has advanced this far. Now there is fast track, QIDP, relatively successful phase 3 and WL, who I am told made another purchase today. Bench players are solid. Gupta did a fine job on the CC.
Badlands, that is not entirely correct. Insmed does have and FDA approved drug that currently is not marketed because of patent infringement some years ago. Below is something the FDA wrote in March 2009
FDA Position on Allowing Patients with ALS Access to Iplex under an IND
Today, the Food and Drug Administration is sharing with the public its decision to allow patients with Amyotrophic Lateral Sclerosis, a fatal neurodegenerative disease also known as Lou Gehrig’s Disease, or ALS, to have access to a drug called Iplex under an Investigational New Drug (IND) application. Iplex (mecasermin rinfabate [rDNA origin] injection), is a combination of two substances: human insulin-like growth factor 1 (IGF-1) and human insulin-like growth factor-binding protein-3 (rhIGFBP-3). Iplex is approved by the FDA only for the treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. The drug is currently not marketed because of a court order related to patent infringement. Iplex is made by Insmed, a biologics company headquartered in Richmond, Virginia.
posting about a shelved drug Iplex is disingenuous at best.There is no production of this very expensive to produce drug _ Iplex ( 18 mos min to get going) since 2009.
Accugrowth gave a heads up last week that we should look to see if that 11M option was indeed taken by Shire for ROP...ROP is the only indication that has shown interest in over 4 years.
& Date Reported
Date Company Symbol Insider
8:50 pm INSMED INC INSM Lewis William
(President and CEO) 7,585 $9.828 $74,547 41,739